78 related articles for article (PubMed ID: 14501384)
1. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.
Majsterek I; Slupianek A; Blasiak J
Anticancer Drugs; 2003 Sep; 14(8):625-31. PubMed ID: 14501384
[TBL] [Abstract][Full Text] [Related]
2. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?
Majsterek I; Slupianek A; Hoser G; Skórski T; Blasiak J
Biochimie; 2004 Jan; 86(1):53-65. PubMed ID: 14987801
[TBL] [Abstract][Full Text] [Related]
3. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
Hoser G; Majsterek I; Romana DL; Slupianek A; Blasiak J; Skorski T
Leuk Res; 2003 Mar; 27(3):267-73. PubMed ID: 12537980
[TBL] [Abstract][Full Text] [Related]
4. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?
Majsterek I; Blasiak J; Mlynarski W; Hoser G; Skórski T
Cell Biol Int; 2002; 26(4):363-70. PubMed ID: 11991666
[TBL] [Abstract][Full Text] [Related]
5. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells.
Błasiak J; Gloc E; Młynarski W; Drzewoski J; Skórski T
Leuk Res; 2002 Dec; 26(12):1093-6. PubMed ID: 12443881
[TBL] [Abstract][Full Text] [Related]
6. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine.
Gloc E; Warszawski M; Młynarski W; Stolarska M; Hoser G; Skorski T; Błasiak J
Acta Biochim Pol; 2002; 49(1):121-8. PubMed ID: 12136932
[TBL] [Abstract][Full Text] [Related]
7. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.
Slupianek A; Hoser G; Majsterek I; Bronisz A; Malecki M; Blasiak J; Fishel R; Skorski T
Mol Cell Biol; 2002 Jun; 22(12):4189-201. PubMed ID: 12024032
[TBL] [Abstract][Full Text] [Related]
8. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine.
Blasiak J; Gloc E; Pertyński T; Drzewoski J
Anticancer Drugs; 2002 Nov; 13(10):1055-60. PubMed ID: 12439339
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin.
Gong S; Guo M; Tang G; Yang J; Qiu H
Chemotherapy; 2018; 63(6):308-314. PubMed ID: 30840968
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
11. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Cramer K; Nieborowska-Skorska M; Koptyra M; Slupianek A; Penserga ET; Eaves CJ; Aulitzky W; Skorski T
Cancer Res; 2008 Sep; 68(17):6884-8. PubMed ID: 18757400
[TBL] [Abstract][Full Text] [Related]
12. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine.
Błasiak J; Gloc E; Woźniak K; Młynarski W; Stolarska M; Skórski T; Majsterek I
Chem Biol Interact; 2002 Apr; 140(1):1-18. PubMed ID: 12044557
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
14. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
Chen J; Wall NR; Kocher K; Duclos N; Fabbro D; Neuberg D; Griffin JD; Shi Y; Gilliland DG
J Clin Invest; 2004 Jun; 113(12):1784-91. PubMed ID: 15199413
[TBL] [Abstract][Full Text] [Related]
15. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
16. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha.
Malinge S; Monni R; Bernard O; Penard-Lacronique V
Oncogene; 2006 Jun; 25(25):3589-97. PubMed ID: 16434962
[TBL] [Abstract][Full Text] [Related]
17. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
[TBL] [Abstract][Full Text] [Related]
19. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
20. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.
Voss J; Posern G; Hannemann JR; Wiedemann LM; Turhan AG; Poirel H; Bernard OA; Adermann K; Kardinal C; Feller SM
Oncogene; 2000 Mar; 19(13):1684-90. PubMed ID: 10763825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
